Ignite Creation Date:
2025-12-24 @ 4:17 PM
Ignite Modification Date:
2026-04-23 @ 5:52 AM
Study NCT ID:
NCT05687266
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-10
First Post:
2022-12-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Sponsor:
AstraZeneca
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
D926NC00001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None